Zsolt Talloczy

880 total citations · 1 hit paper
11 papers, 609 citations indexed

About

Zsolt Talloczy is a scholar working on Rheumatology, Surgery and Hematology. According to data from OpenAlex, Zsolt Talloczy has authored 11 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 3 papers in Surgery and 3 papers in Hematology. Recurrent topics in Zsolt Talloczy's work include Spondyloarthritis Studies and Treatments (7 papers), Rheumatoid Arthritis Research and Therapies (6 papers) and Lipoproteins and Cardiovascular Health (3 papers). Zsolt Talloczy is often cited by papers focused on Spondyloarthritis Studies and Treatments (7 papers), Rheumatoid Arthritis Research and Therapies (6 papers) and Lipoproteins and Cardiovascular Health (3 papers). Zsolt Talloczy collaborates with scholars based in United States, Switzerland and Germany. Zsolt Talloczy's co-authors include Brian Porter, Atul Deodhar, Xenofon Baraliakos, Jürgen Braun, Anastasia Lesogor, Alan Kivitz, Eumorphia Maria Delicha, Xiao Zang, R. Scott Wright and Lawrence A. Leiter and has published in prestigious journals such as Circulation, Frontiers in Immunology and Cardiovascular Research.

In The Last Decade

Zsolt Talloczy

10 papers receiving 601 citations

Hit Papers

Long-term efficacy and safety of inclisiran in patients w... 2023 2026 2024 2025 2023 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
    2023 193 citations Kausik K. Ray, Frank L.J. Visseren et al. The Lancet Diabetes & Endocrinology profile →

Peers

Zsolt Talloczy
Laura Rossetti Italy
Rachel Lorier United States
Alison Taylor United Kingdom
Andreas Perniok Germany
Simon Chivers United Kingdom
Liqi Bi China
Daniel Powers United States
William Koss United States
Shinya Ikoma Japan
Laura Rossetti Italy
Zsolt Talloczy
Citations per year, relative to Zsolt Talloczy Zsolt Talloczy (= 1×) peers Laura Rossetti

Countries citing papers authored by Zsolt Talloczy

Since Specialization
Citations

This map shows the geographic impact of Zsolt Talloczy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zsolt Talloczy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zsolt Talloczy more than expected).

Fields of papers citing papers by Zsolt Talloczy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zsolt Talloczy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zsolt Talloczy. The network helps show where Zsolt Talloczy may publish in the future.

Co-authorship network of co-authors of Zsolt Talloczy

This figure shows the co-authorship network connecting the top 25 collaborators of Zsolt Talloczy. A scholar is included among the top collaborators of Zsolt Talloczy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zsolt Talloczy. Zsolt Talloczy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Wright, R. Scott, Frederick J. Raal, Wolfgang Köenig, et al.. (2024). Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Research. 120(12). 1400–1410. 38 indexed citations
2.
Ray, Kausik K., Frank L.J. Visseren, Lawrence A. Leiter, et al.. (2023). Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. The Lancet Diabetes & Endocrinology. 11(2). 109–119. 193 indexed citations breakdown →
3.
Raal, Frederick J., Ronen Durst, Ran Bi, et al.. (2023). Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 149(5). 354–362. 45 indexed citations
4.
5.
Dougados, Maxime, Uta Kiltz, Alan Kivitz, et al.. (2021). Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials. Rheumatology International. 42(2). 205–213. 4 indexed citations
6.
7.
Baraliakos, Xenofon, Jürgen Braun, Atul Deodhar, et al.. (2019). Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 5(2). e001005–e001005. 64 indexed citations
8.
Emery, Paul, Xenofon Baraliakos, Jürgen Braun, et al.. (2019). 264 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Lara D. Veeken. 58(Supplement_3).
9.
Kivitz, Alan, Ulf Wagner, Eva Dokoupilová, et al.. (2018). Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study. Rheumatology and Therapy. 5(2). 447–462. 83 indexed citations
10.
Braun, Jürgen, Xenofon Baraliakos, Atul Deodhar, et al.. (2018). Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Lara D. Veeken. 58(5). 859–868. 106 indexed citations
11.
Baraliakos, Xenofon, Alan Kivitz, Atul Deodhar, et al.. (2017). Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.. PubMed. 36(1). 50–55. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Rossetti Breakdown of academic impact, for papers by Rachel Lorier Breakdown of academic impact, for papers by Alison Taylor Breakdown of academic impact, for papers by Andreas Perniok Breakdown of academic impact, for papers by Simon Chivers Breakdown of academic impact, for papers by Liqi Bi Breakdown of academic impact, for papers by Daniel Powers Breakdown of academic impact, for papers by William Koss Breakdown of academic impact, for papers by Shinya Ikoma
Rankless by CCL
2026